Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine SR for Smoking Cessation
NCT05066724Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of centanafadine in Tobacco Use Disorder (TUD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Sep 2021; status: completed.
02
Drugs
centanafadine
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05066724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066724.